• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Defensive·301206.SZ
Share

Shandong Sanyuan Biotechnology Co.,Ltd. Stocks

CN¥ 23.7Last Updated 21.09.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 706.94M

CN¥ 23.7
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shandong Sanyuan Biotechnology Co., Ltd., established in 2007 and headquartered in Binzhou, China, specializes in the development, manufacturing, and sale of erythritol and various compound sugar products within the Chinese market. These versatile products find widespread application across numerous industries, serving as ingredients in items such as table and flavored sugars, beverages, candies, chocolate products, baked goods, health foods, pharmaceuticals, cosmetics, and diverse chemical formulations. The company also extends its reach beyond China, distributing its products internationally to regions including Europe, the United States, East Asia, Southeast Asia, Australia, New Zealand, and Africa.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 301206.SZ is 32.0 and suggests 36.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.09.2026 04:06

FT: Citi, Deutsche, and other banks processed $7 billion in Russian payments in defiance of sanctions

22.09.2026 01:05

The Nasdaq set a new record for the first time since June, while the S&P 500 had its best day since August

22.09.2026 00:41

The ECB has launched the first digital euro settlements in the interbank market

21.09.2026 23:48

Meta shares are having their best month in 13 years, with the price at its highest level since October. Is it too late to buy?

21.09.2026 23:31

A $30 Trillion Market and the Risk of an Apocalypse: How Much Could Anthropic Be Worth? — An FT Analysis

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026